Drug intelligence / Profile preview

TINK-104

Development stage: Preclinical
Lead developer: Tinkeso Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

TINK-104 is an allogeneic, off-the-shelf cell therapy composed of unmodified native type III natural killer T (NKT) cells. Developed by Tinkeso Therapeutics, the therapy is designed to treat acute myeloid leukemia (AML) by leveraging the inherent anti-tumor activity of type III NKT cells, which serve as a bridge between the innate and adaptive immune systems. Unlike engineered CAR-NKT therapies, TINK-104 utilizes the natural recognition and effector functions of these cells to target and eliminate leukemic cells. It is currently in the preclinical stage of development and represents a non-engineered approach within Tinkeso's pipeline of NKT cell-based immunotherapies.

Other names: Native type III NKT cell therapy

Beyond the preview

Go deeper on TINK-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TINK-104.

Explore the full profile